Carol Aghajanian, MD | Authors


Using the Angiogenesis Inhibitor Pazopanib to Treat Ovarian Cancer

June 02, 2013

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.